Research & Development

Learn more

INNOVATION IS OUR PRIORITY

10%
10% of VIVACY’s revenue is invested into R&D every year
16
16 years of engagement in research and innovation
#1
Quality and product safety is our #1 priority
x11
Our production capacity has been multiplied by 11 In the past 8 years
2
2 Patented Technologies: IPN-Like, Bi-SOFT®*.
7M
7 million syringes sold in the world between 2008 and 31/08/2018

INNOVATION, A PRIORITY

All Laboratoires VIVACY’s injectable products are designed and developed in the VIVACY Research & Development Laboratory in France, a site that has been entirely dedicated to innovation in the Anti-Ageing and Aesthetics fields.

Laboratoires VIVACY is always seeking to develop innovative, safe and high-quality injectable products that meet patient and doctor expectations and needs, while always remaining compliant with the European and International medical device regulations.

The R&D, Production, Quality & Regulatory Affairs teams collaborate to achieve a common goal: Providing high-end, well tolerated and safe injectable products for patients.

* IPN-Like Technology Patent WO2009/0712697 in 2008 and Bi-SOFT Patent for Laboratoires VIVACY (France), optimised centre of gravity syringe WO2018/185406 A1 in 2018.